Literature DB >> 7138558

The role of the gut flora in the reduction of sulphinpyrazone in the rat.

A G Renwick, S P Evans, T W Sweatman, J Cumberland, C F George.   

Abstract

Sulphinpyrazone underwent both reduction to a sulphide and oxidation to a sulphone after parenteral administration to normal Wistar rats. Oral administration was associated with a bioavailability of about 75% and with a 3-fold greater formation of the sulphide. However, no sulphide was detected in the plasma after oral administration of sulphinpyrazone to germ-free (BD/X) rats or normal rats treated with oral antibiotics. In vitro studies showed that the major site of reduction of sulphinpyrazone was the contents of the hind gut with little activity detected in the liver or other tissues. The sulphide was oxidised in vivo to sulphinpyrazone and small amounts of sulphone, while the latter underwent only slight reduction to sulphinpyrazone, but did not give detectable levels of the sulphide. These data suggest that the gut microflora are the main site of reduction of sulphinpyrazone in the rat in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7138558     DOI: 10.1016/0006-2952(82)90713-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

2.  Biotransformation of BOF-4272, a sulfoxide-containing drug, in the cynomolgus monkey.

Authors:  S Naito; M Nishimura; Y Jin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.441

3.  Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.

Authors:  H A Strong; R Angus; J Oates; J Sembi; P Howarth; A G Renwick; C F George
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

4.  Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.

Authors:  F Schlicht; C Staiger; J de Vries; U Gundert-Remy; R Hildebrandt; J Harenberg; N S Wang; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.

Authors:  W A Ritschel
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

6.  Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study.

Authors:  B S Kuo; W A Ritschel
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.